Table 4.

Association of glycocholenate sulfate, pseudouridine, acisoga and uridine with selected ECG measures, ARIC study, 1987–1989

		PR duration, msa		Abnormal P wave axis		Elevated P wave terminal force in V1
		Diff (95%CI)	P-value	OR (95%CI)	P-value	OR (95%CI)	P-value
Glycocholenate sulfate	Model 1	−0.82 (−1.63, −0.01)	0.05	0.98 (0.86, 1.11)	0.72	1.05 (0.97, 1.14)	0.19
	Model 2	−0.69 (−1.52, 0.13)	0.10	0.95 (0.83, 1.09)	0.45	1.01 (0.93, 1.10)	0.81
	Model 3	−0.69 (−1.52, 0.14)	0.10	0.95 (0.83, 1.09)	0.45	1.01 (0.93, 1.10)	0.81
Pseudouridine	Model 1	0.15 (−0.66, 0.97)	0.71	0.86 (0.74, 1.00)	0.04	1.11(1.03, 1.20)	0.01
	Model 2	−0.56 (−1.39, 0.27)	0.18	0.92 (0.79, 1.06)	0.25	1.03 (0.94, 1.12)	0.55
	Model 3	−0.90 (−1.71, −0.09)	0.03	1.02 (0.89, 1.16)	0.79	1.02 (0.94, 1.11)	0.68
Acisoga	Model 1	−0.52 (−1.31, 0.27)	0.19	1.04 (0.92, 1.18)	0.54	1.07 (0.99, 1.16)	0.09
	Model 2	−0.81 (−1.60, −0.02)	0.05	1.01 (0.89, 1.15)	0.86	1.03 (0.95, 1.11)	0.51
	Model 3	−0.90 (−1.71, −0.09)	0.03	1.02 (0.89, 1.16)	0.79	1.02 (0.94, 1.11)	0.68
Uridine	Model 1	0.79 (0.01, 1.57)	0.05	0.92 (0.81, 1.04)	0.17	0.96 (0.88, 1.04)	0.30
	Model 2	0.58 (−0.21, 1.37)	0.15	1.00 (0.88, 1.15)	0.95	1.00 (0.92, 1.08)	0.93
	Model 3	0.59 (−0.20, 1.38)	0.15	1.00 (0.88, 1.15)	0.96	1.00 (0.92, 1.09)	0.98

Model 1: Adjusted for age, sex, race, study site, and batch. Model 2: As Model 1, additionally adjusted for smoking, body mass index, systolic blood pressure, use of antihypertensive medication, diabetes mellitus, prevalent heart failure and prevalent coronary heart disease. Model 3: As Model 2, additionally adjusted for eGFR

^aModels additionally adjusted for resting heart rate